• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News – India
    • BioMedical
    • BioBusiness
    • BioResearch
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
    • Biotech Express Issues – Access Page
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Editorial: What serious side effects reported after inoculation of Indian COVID-19 vaccines: Survey of AEFI reports
  • COVID-19 scientists are facing an avalanche of abuse, Science survey shows
  • Editorial: Plastic found in human blood – Call an urgency to switch to bioplastic
  • Guestorial: Demand for Nationalization of Healthcare Services in India
  • 19 Year Old Allegedly Dies Post Covishield Vaccination: Kerala High Court Seeks Centre’s Response On Parents’ Plea
  • Phablecare Raises ₹187 Cr In Funding
  • Pfizer Hired 1,800 Additional Employees In 2021 To Process Huge Increase In Vaccine Adverse Events
  • Experts write to PM against WTO proposal on COVID-19 vaccine waivers
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News – India
    • BioMedical
    • BioBusiness
    • BioResearch
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

    January 23, 2022

    Interview – Dr Heera Lal: How an IAS officer using Biotech approaches to transform Indian villages into “Organic Villages”

  • Issues
    • Biotech Express Issues – Access Page
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»Cyrus Poonawalla, the ‘‘Vaccine King’’ awarded Padma Bhushan 2022 for his achievements in biotechnology

Cyrus Poonawalla, the ‘‘Vaccine King’’ awarded Padma Bhushan 2022 for his achievements in biotechnology

0
By Biotech Express on February 25, 2022 Articles, Articles- Editorials, Biotech News - India

This year in 2022, Cyrus Poonawalla again has been conferred Padma Award. He got Padma Shri before in 2005 and thus have joined few elite Indians who consistently are doing for betterment of Indian Biotech and thus getting recognized on national as well as international level.

Cyrus Poonawalla’s life is an excellent example of taking challenges and turning it into opportunity. Though he came from a wealthy family background with an established business, yet he took a chance in a completely new domain when the chances of his survival were limited by government policies and he had to struggle for his survival in rapidly changing India after independence. He had no experience in vaccine development but he tried and hired doctors and scientists and within two years of operations produced the first vaccine. Today he is the most successful Biotechnology entrepreneur and Industrialist with net worth of around 18 billion USD, the richest in Indian Biotechnology and in top 10 richest Indian category.

A conversation with a veterinarian at the farm led him into the world of vaccines. He realized that the farm’s retired horses were donated to the Haffkine Institute, which was owned by the government, to make vaccines from horse serum. Poonawalla thought of trying to meet the demand for vaccines in India by extracting the serum from the horses himself, in order to create vaccines at a much cheaper rate. Dr Balakrishnan, who gave him the idea that would transform his fortunes. He suggested that Cyrus put up a processing plant in a corner of the Poonawalla farm and get into the business himself. The family’s advantage over the big pharma companies was that they had plenty of land to house the horses. The family doctor, Jal Mehta, who subsequently became vice-chairperson of SII, introduced Cyrus to Dr P.M. Wagle, who had just retired as director of the Haffkine Institute. Cyrus employed two scientists to build a small laboratory in a corner of the farm, which had a lot of barren land for breeding.

During his initial years, Poonawalla faced hardships in arranging finances for his company. He started Serum Institution in 1966 with USD 12,000, which he raised by selling horses. In 1966, on Cyrus’s wedding day, the foundation stone for the SI was laid. It was a small-scale industry, with a capital of five lakh rupees to derive therapeutic serum from horse blood.

In 1967 i.e. within three years, Serum launched its first therapeutic tetanus serum and started producing anti-tetanus vaccines of which there was a huge shortage in the country. Cyrus, who has always loved horses, stopped using them to produce the serum, moving on to discarded army mules instead. The company quickly became hugely profitable and branched out into the manufacture of other vaccines.

By 1974, it started making DTP vaccine, which is known to protect children from diphtheria, pertussis, and tetanus. In 1981, it created anti-snake venom serum to treat snakebites. Later, SII specialises in the Tetanus, Measles, Mumps, Rubella, Whooping Cough, Tetanus, Tuberculosis, Influenza, Meningitis, Polio, Rotavirus, Rabies, Pneumonia and several other diseases.

Today in his leadership, Serum Institution turned the world’s largest vaccine manufacturers, catering to 150 countries, including America and European countries. It is also a notable name in producing pediatric vaccines. Serum Institution holds a 60 percent market share in the global vaccine manufacturing segment. Dr. Poonawalla is a person who has always had a vision of creating an atmosphere where high quality vaccines do not remain as a mere luxury for children in India or the world and are offered at inexpensive prices.

Since the beginning, Cyrus focused on producing affordable vaccines to improve the lives of the mass. Some of the vaccines produced by Serum Institution are priced at Rs 5, which is even less than the price of a cup of tea in India. He had the vision to provide high-quality vaccine to all and produced a wide range of pediatric vaccines at an affordable cost. Several international agencies have collaborated with Serum Institution in his noble cause.

 

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Editorial: What serious side effects reported after inoculation of Indian COVID-19 vaccines: Survey of AEFI reports

Editorial: Plastic found in human blood – Call an urgency to switch to bioplastic

Guestorial: Demand for Nationalization of Healthcare Services in India

Leave A Reply Cancel Reply

Current Issue – April 2022

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Editorial: What serious side effects reported after inoculation of Indian COVID-19 vaccines: Survey of AEFI reports April 25, 2022
  • COVID-19 scientists are facing an avalanche of abuse, Science survey shows April 24, 2022
  • Editorial: Plastic found in human blood – Call an urgency to switch to bioplastic April 24, 2022
  • Guestorial: Demand for Nationalization of Healthcare Services in India April 24, 2022
  • 19 Year Old Allegedly Dies Post Covishield Vaccination: Kerala High Court Seeks Centre’s Response On Parents’ Plea April 15, 2022
  • Phablecare Raises ₹187 Cr In Funding April 11, 2022
  • Pfizer Hired 1,800 Additional Employees In 2021 To Process Huge Increase In Vaccine Adverse Events April 9, 2022
  • Experts write to PM against WTO proposal on COVID-19 vaccine waivers April 8, 2022
  • Bose Institute Scientists earn retraction due to manipulation April 5, 2022
  • WHO suspends Covaxin supply to UN agencies April 4, 2022
  • Lockdowns, Not the Pandemic, Created Havoc April 1, 2022
  • WHO selects Biological E to transfer mRNA COVID vaccine tech April 1, 2022
  • Dr. Reddy’s Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany April 1, 2022
  • New Zealand High Court ENDS Vaccine Mandate: “It’s a Gross Violation of Human Rights” April 1, 2022
  • S&T Ministry to support startup in medical implants March 31, 2022
  • FDA Clears Marketing of Genome-Edited Beef Cattle March 30, 2022
  • Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey March 30, 2022
  • Undisclosed industry payments rampant in drug-trial papers in Australia March 29, 2022
  • Fraud Trial of Former Theranos Executive Ramesh’ Sunny’ Balwani Begins March 29, 2022
  • Substandard, fake medical products increased by almost 47% from 2020 to 2021 during pandemic: report March 29, 2022
  • Editorial: Biofuels in India – a perfect waste to wealth and net zero emission energy option March 29, 2022
  • Bharat Biotech and BIOFABRI partner to develop, manufacture and distribute novel TB vaccine March 28, 2022
  • Fibroheal raises debt funding from BIRAC March 28, 2022
  • Editorial – Energy, Renewable Energy and Bioenergy March 28, 2022
  • IISc, India to set up public health centre with Rs105 cr funding from philanthropist March 27, 2022
  • Tamil Nadu makes scientifically dubious claim on vaccines in the Supreme Court March 27, 2022
  • Guest Article: GENE EDITED-CRISPERED FLOWERS: Blooming with grace March 27, 2022
  • Dr. Anthony Fauci, Biden admin operated with missing data as CDC issued pandemic guidance, emails show March 25, 2022
  • Contents – February 2022 March 3, 2022
  • Drs Ella deserve Padma Award for their innovations and management in biotechnology: India’s pioneer recombinant biologist Prof Ramareddy Guntaka February 26, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • Articles- News Reports
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • BioResearch – Industry
  • Biotech – Agriculture
  • Biotech – Healthcare
  • Biotech – Supplies
  • Biotech News – Featured
  • Biotech News – India
  • Biotech News – Industry
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.